Alexander David James

Alexander David James

Auto-generated profile, based on publicly available information

Alexander David James

Novartis Pharma AG Basel Switzerland

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2015 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
AJAlexander James
Alexander James
LBLars Blumenstein
Lars Blumenstein
UGUlrike Glaenzel
Ulrike Glaenzel
YJYi Jin
Yi Jin
ADArnold Demailly
Arnold Demailly
PSPiet Swart
Piet Swart

10 June 2020 in Pharmacology Research & Perspectives
Verified
Journal Article
Open access
PDF file
AJAlexander D. James
Alexander D. James
HSHilmar Schiller
Hilmar Schiller
CMCyrille Marvalin
Cyrille Marvalin
YJYi Jin
Yi Jin
HBHubert Borell
Hubert Borell
GCGian Camenisch
Gian Camenisch
Ribociclib (LEE011, Kisqali ®) is a highly selective small molecule inhibitor of cyclin‐dependent kinases 4 and 6 (CDK4/6), which has been approved for the treatment of advanced or metastatic breast cancer. A human ADME study was conducted in healthy male volunteers following a single oral dose of 600 mg [14C]‐ribociclib. Mass balance, blood and plasma radioactivity, and plasma ribociclib concentrations were measured. Metabolite profiling and identification was conducted in plasma, urine, and feces. An assessment integrating the human ADME results with relevant in vitro and in vivo non‐clinical data was conducted to provide an estimate of the relative contributions of various clearance pathways of the compound. Ribociclib is moderately to highly absorbed across species (approx. 59% in human), and is extensively metabolized in vivo, predominantly by oxidative pathways mediated by CYP3A4 (ultimately forming N‐demethylated metabolite M4) and, to a lesser extent, by FMO3 (N‐hydroxylated metabolite M13). It is extensively distributed in rats, based on QWBA data, and is eliminated rapidly from most tissues with the exception of melanin‐containing structures. Ribociclib passed the placental barrier in rats and rabbits and into milk of lactating rats. In human, 69.1% and 22.6% of the radiolabeled dose were excreted in feces and urine, respectively, with 17.3% and 6.75% of the 14C dose attributable to ribociclib, respectively. The remainder was attributed to numerous metabolites. Taking into account all available data, ribociclib is estimated to be eliminated by hepatic metabolism (approx. 84% of total), renal excretion (7%), intestinal excretion (8%), and biliary elimination (1%).

1 August 2017 in Drug Metabolism and Disposition
Verified
Journal Article
Open access
PDF file
AJAlexander David James
Alexander David James
CMCyrille Marvalin
Cyrille Marvalin
ALAlexandre Luneau
Alexandre Luneau
AMAxel Meissner
Axel Meissner
GCGian Camenisch
Gian Camenisch
The human mass balance study is the definitive study for the assessment of absorption, distribution, metabolism, and excretion (ADME) properties of a new chemical entity in humans. Traditionally this has been carried out by the administration of radiolabeled drug substances, typically 14C or occasionally 3H, as detection methods for these isotopes allow the absolute quantification of drug-related material (DRM) in blood, plasma, and excreta. Coupled with the use of analytical techniques such as liquid chromatography-mass spectrometry, a picture of the metabolic fate of a compound can be elucidated. In this study, we demonstrate the capabilities of 19F nuclear magnetic resonance (NMR) spectroscopy, applied as an alternative to radiolabeling, for the determination of mass balance and for metabolite profiling of an orally administered fluorinated drug. To demonstrate the capabilities of NMR, the study was conducted on remaining samples from a 14C human mass balance study conducted on Alpelisib (BYL719), a compound in late stage development at Novartis for the treatment of solid tumors. Quantitative 14C data were used to cross-validate the data obtained by NMR. The data show that, using 19F NMR, comparable data can be obtained for key human ADME endpoints including mass balance, total DRM determination in plasma and metabolite profiling and identification in plasma and excreta. Potential scenarios where NMR could be employed as an alternative to radiolabeling for the conduct of an early human ADME study are discussed.

12 June 2023 in Drug Metabolism and Disposition
Verified
Journal Article
Open access
PDF file
AJAlexander David James
Alexander David James
KKKenneth Kulmatycki
Kenneth Kulmatycki
BPBirk Poller
Birk Poller
ARAndrea A. Romeo
Andrea A. Romeo
JLJan Jaap Van Lier
Jan Jaap Van Lier
DPDavid Pearson
David Pearson
Iptacopan (LNP023) is an oral, small-molecule, first-in-class, highly potent proximal complement inhibitor that specifically binds factor B and inhibits the alternative complement pathway. Iptacopan is currently in development as a targeted treatment for PNH and multiple other complement-mediated diseases. In this study, the absorption, distribution, metabolism, and excretion (ADME) of iptacopan was characterized in six healthy volunteers after a single 100 mg oral dose of [14C]iptacopan. This was supplemented with an in vivo rat ADME study and metabolite exposure comparisons between human, rat and dog, in addition to in vitro assays, to better understand the clearance pathways and enzymes involved in the metabolism of iptacopan. The fraction of [14C]iptacopan absorbed was estimated to be about 71%, with a time to maximum concentration (Tmax) of 1.5 h and elimination half-life from plasma of 12.3 h. Following a single dose of [14C]iptacopan, 71.5% of the radioactivity was recovered in feces and 24.8% in urine. [14C]iptacopan was primarily eliminated by hepatic metabolism. The main biotransformation pathways were oxidative metabolism via CYP2C8, with M2 being the major oxidative metabolite, and acyl glucuronidation via UGT1A1. The two acyl glucuronide metabolites in human plasma, M8 and M9, each accounted for {less than or equal to}10% of the total circulating drug-related material; systemic exposure was also observed in toxicology studies in rat and dog, suggesting a low risk associated with these metabolites. Binding of iptacopan to its target, factor B, in the bloodstream led to a concentration-dependent blood:plasma distribution and plasma protein binding of [14C]iptacopan. Significance Statement We characterized the pharmacokinetics, excretion, metabolism and elimination of [14C]iptacopan (an oral, selective small-molecule inhibitor of factor B) – in healthy human subjects. [14C]iptacopan was primarily eliminated by metabolism. The primary biotransformation pathways were oxidative metabolism via CYP2C8 and acyl glucuronidation via UGT1A1. Direct secretion of iptacopan into urine and potentially bile represented additional elimination mechanisms. Binding of iptacopan to its target, factor B, in the bloodstream led to a concentration-dependent blood:plasma distribution and plasma protein binding of [14C]iptacopan.

12 January 2024 in Drug Metabolism and Disposition
Verified
Journal Article
Open access
PDF file
FCFilip Cuyckens
Filip Cuyckens
MHMette G. Hvenegaard
Mette G. Hvenegaard
KCKenneth C. Cassidy
Kenneth C. Cassidy
DSDouglas K. Spracklin
Douglas K. Spracklin
AJAlexander D. James
Alexander D. James
GYGraeme C. Young
Graeme C. Young
The administration of radiolabeled drug candidates is considered the gold standard in absorption, distribution, metabolism and excretion (ADME) studies for small molecule drugs, since it allows facile and accurate quantification of parent drug, metabolites and total drug related material independent of the compound structure. The choice of the position of the radiolabel, typically 14C or 3H, is critical to obtain relevant information. Sometimes a biotransformation reaction may lead to cleavage of a part of the molecule. As a result only the radiolabeled portion can be followed while information on the fate of the non-labeled metabolite may be lost. Synthesis and administration of two or more radiolabeled versions of the parent drug as a mixture or in separate studies may resolve this issue, but comes with additional challenges. In this paper we address the questions that may be considered to help make the right choice whether to use single or a multiple radiolabel approach, discuss pros and cons of different multiple labeling strategies that can be taken as well as alternative methods that allow the non-labeled part of the molecule to be followed. Significance Statement Radiolabeled studies are the gold standard in drug metabolism research, but molecules can undergo cleavage with loss of the label. This often results in discussions around potential use of multiple labels which seem to be occurring with increased frequency since an increasing proportion of the “small molecule drugs” are tending towards larger molecular weights. This review provides insight and decision criteria in considering a multiple label approach as well as pros and cons of different strategies that can be followed.

22 December 2023 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
GYGraeme C. Young
Graeme C. Young
DSDouglas K. Spracklin
Douglas K. Spracklin
AJAlexander D. James
Alexander D. James
MHMette G. Hvenegaard
Mette G. Hvenegaard
MPMette L. Pedersen
Mette L. Pedersen
GSGraeme Scarfe
Graeme Scarfe
A review of the use of microdoses and isotopic microtracers for clinical intravenous pharmacokinetic (i.v. PK) data provision is presented. The extent of application of the varied approaches available and the relative merits of each are highlighted with the aim of assisting practitioners in making informed decisions on the most scientifically appropriate design to adopt for any given new drug in development. It is envisaged that significant efficiencies will be realized as i.v. PK data in humans becomes more routinely available for suitable assets in early development, than has been the case prior to the last decade.